Inclusion Criteria:  Age 65-85 years; female must be post-menopausal for ≥ 2 consecutive years Probable mild AD according to the core clinical criteria outlined in the National Institute on Aging/Alzheimer's Association (NIA-AA) Guidelines MMSE score between the range of 21 to 27; CDR score of 1.0 (mild AD); scores on Logical Memory II subscale (Delayed Recall) from the Wechsler Memory Scale-Revised (WMS) within the recommended education-adjusted ranges Have either cerebrospinal fluid (CSF) Aβ42 levels that are consistent with Alzheimer's disease as measured via mass spectrometry by C2N, or document elevated amyloid burden consistent with Alzheimer's disease from positron emission tomography (PET) imaging Screening MRI without evidence of infection, infarction, or other focal lesions of neurological disease; and no significant nasal disease. All participants must have a study partner with normal cognitive function.  Exclusion Criteria:  Any significant neurologic disease Major psychiatric disorder within the past 2 years Substance use disorder within the past 2 years Any unstable medical condition Contraindications to MRI Any Alzheimer's disease modifying therapy (DMT) in the past 6 months Antipsychotics, anticholinergics, anticonvulsants, and other antidepressants, benzodiazepines, or other psychotropic medications and blood thinners, except for aspirin at a prophylactic dose or less.